)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
Ryvu Therapeutics
Ryvu Therapeutics (RVU) investor relations material
Ryvu Therapeutics Q2 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q2 2026 earnings summary17 Sep, 2026
Executive summary
Operating revenue for H1 2026 was PLN 38.7m, down from PLN 42.4m year-over-year, mainly due to lower subsidies and sales, partially offset by higher R&D project revenue.
Net loss for H1 2026 was PLN 25.7m, a significant improvement from PLN 58.9m in H1 2025, reflecting reduced operating costs and strategic portfolio prioritization.
Strategic focus shifted to romaciclib (RVU120) in relapsed/refractory AML, with expansion of the RIVER-81 Phase II study and closure of the POTAMI-61 myelofibrosis study.
Launch of Keelira, a new early clinical development services business, to diversify revenue streams.
Financial highlights
Total assets as of June 30, 2026: PLN 182.6m, down from PLN 224.4m at year-end 2025.
Cash and cash equivalents: PLN 50.7m (down from PLN 59.6m at year-end 2025); total cash and investments: PLN 74.7m.
Operating expenses (excluding incentive scheme and Nodthera valuation) decreased to PLN 67.6m from PLN 95.5m year-over-year.
EBITDA for H1 2026 was negative PLN 24.7m, improved from negative PLN 60.6m in H1 2025.
Book value per share as of June 30, 2026: PLN 1.23 (down from PLN 4.12 at year-end 2025).
Outlook and guidance
Adequate liquidity maintained to fund planned operations, supported by EIB financing and ongoing cost discipline.
Future results will depend on advancing romaciclib in AML, achieving milestones in partnered programs, and expanding Keelira's client base.
Additional non-dilutive financing options and strategic partnerships are being pursued.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Ryvu Therapeutics
- Romaciclib demonstrates strong clinical promise in AML and MF, driving accelerated development.RVU
Corporate presentation - Romaciclib demonstrates strong clinical promise in AML and MF, backed by key partnerships and funding.RVUCorporate presentation
- Romaciclib demonstrates promising efficacy in AML, driving accelerated development and global expansion.RVUCorporate presentation
- Romaciclib delivers promising results in AML and MF, driving a robust oncology pipeline.RVUCorporate presentation
- Net loss narrowed and cash reserves remain strong, with new grants and collaborations secured.RVUQ1 2026
- Romaciclib delivers promising results in AML and MF, driving a robust oncology pipeline and partnerships.RVUCorporate presentation
- Romaciclib delivers promising results in AML and MF, with a robust pipeline and strong partnerships.RVUCorporate presentation
- Revenue fell and losses increased, but pipeline progress and new funding support future prospects.RVUQ3 2025
- Phase II studies show early efficacy and safety for RVU120; key data expected H1 2025.RVUStudy Update
Next Ryvu Therapeutics earnings date
Q3 202619 Nov, 2026
Ryvu Therapeutics
Next Ryvu Therapeutics earnings date
Q3 202619 Nov, 2026
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
Ryvu Therapeutics S.A. is a Poland-based biotechnology company focused on the research and development of novel small molecule therapies. The company specializes in discovering and developing treatments for cancer, particularly in the areas of targeted therapies and immuno-oncology. Ryvu conducts both early-stage discovery and clinical development activities, with a pipeline supported by internal research capabilities and collaborative partnerships. The company is headquartered in Kraków, Poland, and its shares are listed on the WSE.